Sparsentan is an endothelin and angiotensin II receptor antagonist indicated to slow kidney function decline for adults with primary IgA nephropathy who are at risk for disease progression.

Multiple medications are now available to treat IgA nephropathy, including budesonide (Tarpeyo), sparsentan (Filspari), and iptacopan (Fabhalta). But Miller’s treatment options were more limited ...

BOSTON -- Patients with focal segmental glomerulosclerosis (FSGS) achieved some degree of proteinuria remission more often ...

Travere Therapeutics and partner CSL Vifor could be weeks away from EU approval of sparsentan for IgA nephropathy, after getting a positive opinion on the drug from the EMA’s human medicines ...

The late-breaking oral presentation will feature new analyses from the Phase 3 DUPLEX Study of FILSPARI® (sparsentan ... as a foundational therapy in IgA nephropathy (IgAN).

IgA nephropathy (IgAN), also called Berger's ... Concomitant use with a strong CYP3A inhibitor increases sparsentan exposure which may increase the risk of FILSPARI adverse reactions.

The late-breaking oral presentation will feature new analyses from the Phase 3 DUPLEX Study of FILSPARI® (sparsentan) in focal segmental ... the role of FILSPARI as a foundational therapy in IgA ...

Ligand Pharmaceuticals offers biotech exposure with reduced risk through its royalty platform. Discover why its valuation now ...

IgA nephropathy drugs that work via other mechanisms include delayed-release budesonide (Tarpeyo), sparsentan (Filspari), and iptacopan (Fabhalta). "Today's approval marks an important milestone ...